GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gan & Lee Pharmaceuticals Co Ltd (SHSE:603087) » Definitions » Forward PE Ratio

Gan & Lee Pharmaceuticals Co (SHSE:603087) Forward PE Ratio : 27.32 (As of May. 12, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Gan & Lee Pharmaceuticals Co Forward PE Ratio?

Gan & Lee Pharmaceuticals Co's Forward PE Ratio for today is 27.32.

Gan & Lee Pharmaceuticals Co's PE Ratio without NRI for today is 41.44.

Gan & Lee Pharmaceuticals Co's PE Ratio (TTM) for today is 36.04.


Gan & Lee Pharmaceuticals Co Forward PE Ratio Historical Data

The historical data trend for Gan & Lee Pharmaceuticals Co's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gan & Lee Pharmaceuticals Co Forward PE Ratio Chart

Gan & Lee Pharmaceuticals Co Annual Data
Trend 2024-12
Forward PE Ratio
23.76

Gan & Lee Pharmaceuticals Co Quarterly Data
2024-12 2025-03
Forward PE Ratio 23.76 24.38

Competitive Comparison of Gan & Lee Pharmaceuticals Co's Forward PE Ratio

For the Medical Instruments & Supplies subindustry, Gan & Lee Pharmaceuticals Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gan & Lee Pharmaceuticals Co's Forward PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gan & Lee Pharmaceuticals Co's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Gan & Lee Pharmaceuticals Co's Forward PE Ratio falls into.


;
;

Gan & Lee Pharmaceuticals Co Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Gan & Lee Pharmaceuticals Co  (SHSE:603087) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Gan & Lee Pharmaceuticals Co Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Gan & Lee Pharmaceuticals Co's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gan & Lee Pharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
No. 8, 1st Nanfeng West Road, Zhenxian Town, Tongzhou District, Beijing, CHN, 101102
Gan & Lee Pharmaceuticals Co Ltd is a biopharmaceutical company specialized in research, development, production and commercialization of insulin and its analogues in the diabetes market in China. The company is engaged in production and sales of recombinant insulin analog raw materials and injections. It has launched multiple biosimilar insulin analogue products, including the super long-acting insulin glargine Basalin, the super quick-acting insulin lispro Prandilin, and the pre-mixed insulin analogue Prandilin 25.
Executives
Gan Zhong Ru Director

Gan & Lee Pharmaceuticals Co Headlines

No Headlines